Jiqing Ye

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Multidrug Resistant

Staphylococcus Aureus

Structure Activity Relationship

Molecular Dynamics

Top Venues

International journal of molecular sciences

RSC medicinal chemistry

Pharmaceuticals (Basel, Switzerland)

Pathogens (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Jiqing Ye, Cheuk Hei Kan, Xiao Yang, Cong Ma
Inhibition of bacterial RNA polymerase function and protein-protein interactions: a promising approach for next-generation antibacterial therapeutics. RSC medicinal chemistry 15 (5) (2024)
Jiqing Ye, Cheuk Hei Kan, Xiao Yang, Cong Ma
Inhibition of bacterial RNA polymerase function and protein-protein interactions: a promising approach for next-generation antibacterial therapeutics. RSC medicinal chemistry 15 (5) (2024)
Jiqing Ye, Xiao Yang, Cong Ma
Ligand-Based Drug Design of Novel Antimicrobials against Staphylococcus aureus by Targeting Bacterial Transcription. International journal of molecular sciences 24 (1) (2022)
Renee Wan Yi Chan, Kin P Tao, Jiqing Ye, Kevin K Y Lui, Xiao Yang, Cong Ma, Paul Kay Sheung Chan
Inhibition of Influenza Virus Replication by Oseltamivir Derivatives. Pathogens (Basel, Switzerland) 11 (2) (2022)
Jiqing Ye, Xiao Yang, Cong Ma
Ligand-Based Drug Design of Novel Antimicrobials against Staphylococcus aureus by Targeting Bacterial Transcription. International journal of molecular sciences 24 (1) (2022)
Jiqing Ye, Xiao Yang, Cong Ma
QSAR, Docking, and Molecular Dynamics Simulation Studies of Sigmacidins as Antimicrobials against Streptococci . International journal of molecular sciences 23 (8) (2022)
Jiqing Ye, Xiao Yang, Cong Ma
Ligand-Based Drug Design of Novel Antimicrobials against Staphylococcus aureus by Targeting Bacterial Transcription. International journal of molecular sciences 24 (1) (2022)
Jiqing Ye, Lin Lin, Jinyi Xu, Paul Kay-Sheung Chan, Xiao Yang, Cong Ma
Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors. Pharmaceuticals (Basel, Switzerland) 14 (4) (2021)